Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTN7HMG)

DTT Name	Teratocarcinoma-derived growth factor 1 (TDGF1)
Synonyms	TDGF1; Epidermal growth factor-like cripto protein CR1; Cripto-1 growth factor; Cripto; CRGF
Gene Name	TDGF1
DTT Type	Clinical trial target	[1]
BioChemical Class	Growth factor
UniProt ID	TDGF1_HUMAN
TTD ID	T47864
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MDCRKMARFSYSVIWIMAISKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWPQEEPAIR PRSSQRVPPMGIQHSKELNRTCCLNGGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPH DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLVGI CLSIQSYY
Function	Could play a role in the determination of the epiblastic cells that subsequently give rise to the mesoderm.
Reactome Pathway	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation (R-HSA-2892247 ) Regulation of signaling by NODAL (R-HSA-1433617 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIIB 015	DM5AW7J	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

References

1	An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46.